Use of granulocyte growth factors: recommendations of the Portuguese Society of Hematology.

Authors

  • João Forjaz de Lacerda Serviço de Hematologia e Transplantação de Medula, Hospital de Santa Maria, Lisbon.
  • Fernando Leal da Costa
  • Ana Marques Pereira
  • Fernando Príncipe
  • Adriana Teixeira
  • António Parreira

DOI:

https://doi.org/10.20344/amp.1644

Abstract

The administration of cytotoxic chemotherapy may be complicated by the emergence of neutropenia and febrile neutropenia, frequently determining hospital admission and intravenous treatment with broad spectrum antibiotics. Frequently, it is necessary to reduce the dose or to delay the administration of the cytotoxic drugs reducing the relative dose intensity of the chemotherapy regimen. Granulocyte growth factors stimulate the proliferation and differentiation of neutrophils and reduce the number of days of severe neutropenia and febrile neutropenia associated with cytotoxic chemotherapy. They are also indicated for the collection of hematopoietic progenitors for autologous and allogeneic transplantation, as well as in non malignant diseases associated with chronic neutropenia. This article reviews the evidence supporting the use of granulocyte growth factors in Hematology.

Downloads

Download data is not yet available.

How to Cite

1.
Forjaz de Lacerda J, Leal da Costa F, Marques Pereira A, Príncipe F, Teixeira A, Parreira A. Use of granulocyte growth factors: recommendations of the Portuguese Society of Hematology. Acta Med Port [Internet]. 2008 Oct. 30 [cited 2024 Mar. 29];21(5):412-26. Available from: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1644

Issue

Section

Arquivo Histórico